Galera Therapeutics, Inc. Common Stock
GRTX
GRTX was delisted on the 3rd of June, 2024.
34 hedge funds and large institutions have $160M invested in Galera Therapeutics, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 4 closing their positions.
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
6% more funds holding
Funds holding: 32 → 34 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
28% less capital invested
Capital invested by funds: $224M → $160M (-$63.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.09M |
| 2 |
State Street
Boston,
Massachusetts
|
+$194K |
| 3 |
Squarepoint
New York
|
+$163K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$153K |
| 5 |
Bank of New York Mellon
New York
|
+$149K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$2.08M |
| 2 |
Millennium Management
New York
|
-$664K |
| 3 |
Norges Bank
Oslo,
Norway
|
-$354K |
| 4 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$207K |
| 5 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
-$148K |
GRTX Hedge Fund Activity: Q1 2020 in Review
34 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Galera Therapeutics, Inc. Common Stock (GRTX) for Q1 2020, worth a combined $160M — down 28% from $224M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new GRTX positions and 4 closed out — a net gain of 2 holders — while 12 added to existing stakes and 8 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.09M. The largest seller was RA Capital Management, cutting an estimated $2.08M.
- 34 institutional investors held Galera Therapeutics, Inc. Common Stock (GRTX) as of Q1 2020, up from 32 in Q4 2019.
- Funds reported $160M of Galera Therapeutics, Inc. Common Stock stock for Q1 2020, down 28% quarter-over-quarter.
- 6 funds opened new Galera Therapeutics, Inc. Common Stock positions in Q1 2020 and 4 closed out, a net change of +2 holders.
- The largest Galera Therapeutics, Inc. Common Stock buyer in Q1 2020 was Vanguard Group, an estimated $1.09M added.
- The largest Galera Therapeutics, Inc. Common Stock seller in Q1 2020 was RA Capital Management, an estimated $2.08M sold.
Based on aggregated 13F filings for Q1 2020.